<DOC>
	<DOCNO>NCT01343264</DOCNO>
	<brief_summary>The role surgical resection management Malignant Pleural Mesothelioma ( MPM ) still controversial . The selection criterion perform either Extrapleural Pneumonectomy ( EPP ) Pleurectomy/Decortication ( P/D ) dependent cardio-pulmonary status patient , tumor stage intraoperative finding also surgeon ' decision philosophy . There establish guideline . Radical Pleurectomy ( RP ) compete EPP surgical therapy modality . Both surgical approach cytoreductive treatment option . The aim remove gross disease achieve macroscopic complete resection . Originally P/D palliative option control pleural effusion . But lung-sparing surgery MPM seem alternative patient unsuitable unwilling undergo EPP multimodality therapy concept . Most study evaluate multimodality therapy MPM base retrospective analysis interpretation difficult inhomogeneous patient group study . The aim study analyze feasibility result RP surgical therapy modality standardize trimodality therapy concept .</brief_summary>
	<brief_title>Trimodality Therapy Malignant Pleural Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm diagnosis MPM ( subtypes ) Clinical T13 , N02 , M0 disease . No prior treatment MPM . Adequate renal liver function Adequate cardiopulmonary reserve Patients unresectable disease Patients active infection require systemic treatment Patients concurrent active malignancy . Patients serious medical illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Radical Pleurectomy</keyword>
	<keyword>Pleurectomy/decortication</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Radiation</keyword>
</DOC>